100 related articles for article (PubMed ID: 20949429)
1. Single-dose oral pharmacokinetics of pergolide mesylate in healthy adult mares.
Gehring R; Beard L; Wright A; Coetzee J; Havel J; Apley M
Vet Ther; 2010; 11(1):E1-8. PubMed ID: 20949429
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of pergolide after intravenous administration to horses.
Rendle DI; Hughes KJ; Doran GS; Edwards SH
Am J Vet Res; 2015 Feb; 76(2):155-60. PubMed ID: 25629913
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and pharmacodynamics of pergolide mesylate after oral administration in horses with pituitary pars intermedia dysfunction.
Rendle DI; Doran G; Ireland J; Edwards S
Domest Anim Endocrinol; 2019 Jul; 68():135-141. PubMed ID: 31082785
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
McFarlane D; Banse H; Knych HK; Maxwell LK
J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
[TBL] [Abstract][Full Text] [Related]
5. Restoring pars intermedia dopamine concentrations and tyrosine hydroxylase expression levels with pergolide: evidence from horses with pituitary pars intermedia dysfunction.
Fortin JS; Benskey MJ; Lookingland KJ; Patterson JS; Howey EB; Goudreau JL; Schott HC
BMC Vet Res; 2020 Sep; 16(1):356. PubMed ID: 32977825
[TBL] [Abstract][Full Text] [Related]
6. Determination of pergolide in horse plasma by UPLC-MS/MS for pharmacokinetic applications.
Jacobson GA; Pirie A; Edwards S; Hughes KJ; Rendle DI; Davies NW
J Pharm Biomed Anal; 2014 Jun; 94():54-7. PubMed ID: 24549007
[TBL] [Abstract][Full Text] [Related]
7. Comparison of hair follicle histology between horses with pituitary pars intermedia dysfunction and excessive hair growth and normal aged horses.
Innerå M; Petersen AD; Desjardins DR; Steficek BA; Rosser EJ; Schott HC
Vet Dermatol; 2013 Feb; 24(1):212-7.e46-7. PubMed ID: 23331700
[TBL] [Abstract][Full Text] [Related]
8. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).
Donaldson MT; LaMonte BH; Morresey P; Smith G; Beech J
J Vet Intern Med; 2002; 16(6):742-6. PubMed ID: 12465775
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics of pergolide in Parkinson's disease.
Blin O
Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S9-12. PubMed ID: 15180132
[TBL] [Abstract][Full Text] [Related]
10. Case series of equine pituitary pars intermedia dysfunction in a tropical climate.
Spelta CW; Axon JE
Aust Vet J; 2012 Nov; 90(11):451-6. PubMed ID: 23106327
[TBL] [Abstract][Full Text] [Related]
11. Nitration and increased alpha-synuclein expression associated with dopaminergic neurodegeneration in equine pituitary pars intermedia dysfunction.
McFarlane D; Dybdal N; Donaldson MT; Miller L; Cribb AE
J Neuroendocrinol; 2005 Feb; 17(2):73-80. PubMed ID: 15796757
[TBL] [Abstract][Full Text] [Related]
12. Markers of muscle atrophy and impact of treatment with pergolide in horses with pituitary pars intermedia dysfunction and muscle atrophy.
Banse HE; Whitehead AE; McFarlane D; Chelikani PK
Domest Anim Endocrinol; 2021 Jul; 76():106620. PubMed ID: 33740552
[TBL] [Abstract][Full Text] [Related]
13. Preliminary study on the effects of pergolide on left ventricular function in the horses with pituitary pars intermedia dysfunction.
Gehlen H; Fisch J; Merle R; Trachsel DS
J Vet Sci; 2021 Sep; 22(5):e64. PubMed ID: 34553515
[TBL] [Abstract][Full Text] [Related]
14. Equine pituitary pars intermedia dysfunction.
McFarlane D
Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic properties of pergolide mesylate following single and multiple-dose administration in donkeys (Equus asinus).
Xue C; Davis J; Berghaus LJ; Hanafi A; Vaughn SA; Hart KA
Equine Vet J; 2023 Nov; 55(6):1078-1085. PubMed ID: 36572900
[TBL] [Abstract][Full Text] [Related]
16. Equine pituitary pars intermedia dysfunction: current perspectives on diagnosis and management.
Spelta CW
Vet Med (Auckl); 2015; 6():293-300. PubMed ID: 30101114
[TBL] [Abstract][Full Text] [Related]
17. Pergolide dosing compliance and factors affecting the laboratory control of equine pituitary pars intermedia dysfunction.
Hague N; Durham AE; Menzies-Gow NJ
Vet Rec; 2021 Jul; 189(1):e142. PubMed ID: 33759215
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of pergolide for the management of equine pituitary pars intermedia dysfunction: A systematic review.
Tatum RC; McGowan CM; Ireland JL
Vet J; 2020 Dec; 266():105562. PubMed ID: 33323174
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses.
McGowan TW; Pinchbeck GP; McGowan CM
Equine Vet J; 2013 Jan; 45(1):74-9. PubMed ID: 22594955
[TBL] [Abstract][Full Text] [Related]
20. Pituitary pars intermedia dysfunction (equine Cushing's disease) in a Thoroughbred stallion: a single report.
Hatazoe T; Kawaguchi H; Hobo S; Misumi K
J Equine Sci; 2015; 26(4):125-8. PubMed ID: 26858577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
